Association between FGF19, FGF21 and lipocalin-2, and diabetes progression in PCOS
Women with polycystic ovary syndrome (PCOS) have an increased risk of developing type 2 diabetes. FGF19, FGF21 and lipocalin-2 have emerged as important markers of metabolic risk. This study aims to compare the levels of FGF19, FGF21 and lipocalin-2 between subjects with or without PCOS, and to inve...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Bioscientifica
2021-10-01
|
Series: | Endocrine Connections |
Subjects: | |
Online Access: | https://ec.bioscientifica.com/view/journals/ec/10/10/EC-21-0082.xml |
id |
doaj-26823229e1c84292b2f28809f7ac16bc |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Feifei Cheng Noel Yat Hey Ng Claudia Ha Ting Tam Yuying Zhang Cadmon King Poo Lim Guozhi Jiang Alex Chi Wai Ng Tiffany Tse Ling Yau Lai Ping Cheung Aimin Xu Juliana C N Chan Ronald C W Ma |
spellingShingle |
Feifei Cheng Noel Yat Hey Ng Claudia Ha Ting Tam Yuying Zhang Cadmon King Poo Lim Guozhi Jiang Alex Chi Wai Ng Tiffany Tse Ling Yau Lai Ping Cheung Aimin Xu Juliana C N Chan Ronald C W Ma Association between FGF19, FGF21 and lipocalin-2, and diabetes progression in PCOS Endocrine Connections polycystic ovary syndrome type 2 diabetes fgf19 fgf21 lipocalin-2 |
author_facet |
Feifei Cheng Noel Yat Hey Ng Claudia Ha Ting Tam Yuying Zhang Cadmon King Poo Lim Guozhi Jiang Alex Chi Wai Ng Tiffany Tse Ling Yau Lai Ping Cheung Aimin Xu Juliana C N Chan Ronald C W Ma |
author_sort |
Feifei Cheng |
title |
Association between FGF19, FGF21 and lipocalin-2, and diabetes progression in PCOS |
title_short |
Association between FGF19, FGF21 and lipocalin-2, and diabetes progression in PCOS |
title_full |
Association between FGF19, FGF21 and lipocalin-2, and diabetes progression in PCOS |
title_fullStr |
Association between FGF19, FGF21 and lipocalin-2, and diabetes progression in PCOS |
title_full_unstemmed |
Association between FGF19, FGF21 and lipocalin-2, and diabetes progression in PCOS |
title_sort |
association between fgf19, fgf21 and lipocalin-2, and diabetes progression in pcos |
publisher |
Bioscientifica |
series |
Endocrine Connections |
issn |
2049-3614 |
publishDate |
2021-10-01 |
description |
Women with polycystic ovary syndrome (PCOS) have an increased risk of developing type 2 diabetes. FGF19, FGF21 and lipocalin-2 have emerged as important markers of metabolic risk. This study aims to compare the levels of FGF19, FGF21 and lipocalin-2 between subjects with or without PCOS, and to investigate the relationship between proteins and diabetes progression. In this nested case–control cohort study, 128 Chinese PCOS women and 128 controls were recruited and followed-up. All subjects underwent the oral glucose tolerance test for the evaluation of glycaemic status. Baseline serum protein levels were measured using ELISA. Compared with controls, PCOS subjects had higher levels of FGF19 (P < 0.001) and FGF21 (P = 0.022), but had lower lipocalin-2 (P < 0.001). In total, 20.8% of PCOS and 9.2% of controls developed diabetes over a mean duration of 10.4 ± 1.2 and 11.3 ± 0.5 years, respectively. Logistic regression analyses suggested FGF19 was positively associated with diabetes progression in controls, after adjusting for age, follow-up duration, waist and fasting glucose (P = 0.026, odds ratio (OR) (95% CI): 7.4 (1.3–43.6)), and the positive relationship between FGF21 and diabetes progression in controls was attenuated by adjusting for age and follow-up duration (P = 0.183). Lipocalin-2 was positively correlated with diabetes progression in PCOS group (P = 0.026, OR (95% CI)): 2.5 (1.1–5.6)); however, this became attenuated after adjusting for waist and fasting glucose (P = 0.081). In conclusion, there is differential expression of FGF1 9, FGF21, and lipocalin-2 in PCOS. The serum level of FGF19, and FGF21 is associated with diabetes progression in women without PCOS, while lipocalin-2 was related to diabetes progression in PCOS women. |
topic |
polycystic ovary syndrome type 2 diabetes fgf19 fgf21 lipocalin-2 |
url |
https://ec.bioscientifica.com/view/journals/ec/10/10/EC-21-0082.xml |
work_keys_str_mv |
AT feifeicheng associationbetweenfgf19fgf21andlipocalin2anddiabetesprogressioninpcos AT noelyatheyng associationbetweenfgf19fgf21andlipocalin2anddiabetesprogressioninpcos AT claudiahatingtam associationbetweenfgf19fgf21andlipocalin2anddiabetesprogressioninpcos AT yuyingzhang associationbetweenfgf19fgf21andlipocalin2anddiabetesprogressioninpcos AT cadmonkingpoolim associationbetweenfgf19fgf21andlipocalin2anddiabetesprogressioninpcos AT guozhijiang associationbetweenfgf19fgf21andlipocalin2anddiabetesprogressioninpcos AT alexchiwaing associationbetweenfgf19fgf21andlipocalin2anddiabetesprogressioninpcos AT tiffanytselingyau associationbetweenfgf19fgf21andlipocalin2anddiabetesprogressioninpcos AT laipingcheung associationbetweenfgf19fgf21andlipocalin2anddiabetesprogressioninpcos AT aiminxu associationbetweenfgf19fgf21andlipocalin2anddiabetesprogressioninpcos AT julianacnchan associationbetweenfgf19fgf21andlipocalin2anddiabetesprogressioninpcos AT ronaldcwma associationbetweenfgf19fgf21andlipocalin2anddiabetesprogressioninpcos |
_version_ |
1716843245129957376 |
spelling |
doaj-26823229e1c84292b2f28809f7ac16bc2021-10-05T11:15:30ZengBioscientificaEndocrine Connections2049-36142021-10-01101012431252https://doi.org/10.1530/EC-21-0082Association between FGF19, FGF21 and lipocalin-2, and diabetes progression in PCOSFeifei Cheng0Noel Yat Hey Ng1Claudia Ha Ting Tam2Yuying Zhang3Cadmon King Poo Lim4Guozhi Jiang5Alex Chi Wai Ng6Tiffany Tse Ling Yau7Lai Ping Cheung8Aimin Xu9Juliana C N Chan10Ronald C W Ma11Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong KongDepartment of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong KongDepartment of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong; Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Hong Kong, Hong Kong Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong; Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Hong Kong, Hong Kong Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong; Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, Hong Kong Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong; Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Hong Kong, Hong Kong Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong KongDepartment of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong KongDepartment of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Hong Kong, Hong KongDepartment of Medicine, Li Ka Shing (LKS) Faculty of Medicine, University of Hong Kong, Hong Kong, Hong Kong; State Key Laboratory of Pharmaceutical Biotechnology, University of Hong Kong, Hong Kong, Hong Kong; Department of Pharmacy and Pharmacology, LKS Faculty of Medicine, University of Hong Kong, Hong Kong, Hong Kong Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong; Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Hong Kong, Hong Kong; Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, Hong Kong; Chinese University of Hong Kong-Shanghai Jiao Tong University Joint Research Centre in Diabetes Genomics and Precision Medicine, Hong Kong, Hong Kong Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong; Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Hong Kong, Hong Kong; Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, Hong Kong; Chinese University of Hong Kong-Shanghai Jiao Tong University Joint Research Centre in Diabetes Genomics and Precision Medicine, Hong Kong, Hong Kong Women with polycystic ovary syndrome (PCOS) have an increased risk of developing type 2 diabetes. FGF19, FGF21 and lipocalin-2 have emerged as important markers of metabolic risk. This study aims to compare the levels of FGF19, FGF21 and lipocalin-2 between subjects with or without PCOS, and to investigate the relationship between proteins and diabetes progression. In this nested case–control cohort study, 128 Chinese PCOS women and 128 controls were recruited and followed-up. All subjects underwent the oral glucose tolerance test for the evaluation of glycaemic status. Baseline serum protein levels were measured using ELISA. Compared with controls, PCOS subjects had higher levels of FGF19 (P < 0.001) and FGF21 (P = 0.022), but had lower lipocalin-2 (P < 0.001). In total, 20.8% of PCOS and 9.2% of controls developed diabetes over a mean duration of 10.4 ± 1.2 and 11.3 ± 0.5 years, respectively. Logistic regression analyses suggested FGF19 was positively associated with diabetes progression in controls, after adjusting for age, follow-up duration, waist and fasting glucose (P = 0.026, odds ratio (OR) (95% CI): 7.4 (1.3–43.6)), and the positive relationship between FGF21 and diabetes progression in controls was attenuated by adjusting for age and follow-up duration (P = 0.183). Lipocalin-2 was positively correlated with diabetes progression in PCOS group (P = 0.026, OR (95% CI)): 2.5 (1.1–5.6)); however, this became attenuated after adjusting for waist and fasting glucose (P = 0.081). In conclusion, there is differential expression of FGF1 9, FGF21, and lipocalin-2 in PCOS. The serum level of FGF19, and FGF21 is associated with diabetes progression in women without PCOS, while lipocalin-2 was related to diabetes progression in PCOS women.https://ec.bioscientifica.com/view/journals/ec/10/10/EC-21-0082.xmlpolycystic ovary syndrometype 2 diabetesfgf19fgf21lipocalin-2 |